Close Menu

GenMark

Of the 31 companies in the index, 11 firms saw their stock prices increase, while 20 saw their share prices decline.

News items for the in vitro diagnostics industry for the week of March 22, 2021.

Roche Diagnostics CEO Thomas Schinecker said the infrastructure put in place due to the pandemic will allow for more diagnostic testing globally.

Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.

Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.

The firm said it is drawing up plans for its business in a post-pandemic world, planning the introduction of new testing panels and enhancing its respiratory panel.

GenMark said its ePlex molecular diagnostic product revenue for Q4 was $45.4 million, an increase of 138 percent over the fourth quarter of 2019.

Investors reacted favorably to a report Wednesday evening saying the Carlsbad, California-based firm is working with a financial advisor on a potential sale.

Of the 32 companies in the index, 27 firms saw their stock prices increase, while 5 saw their share prices decline.

Qiagen discussed what's in store after a failed bid by Thermo Fisher Scientific, and COVID-19 remained a hot topic on the second day of the virtual conference.

Pages